Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2655${count})

  • Novel PET Tracer Development Program, 2022
    Screening for PET Tracers that will Bind to the P2Y12 Receptor and Allow Monitoring of Microglia Activation During Neuroinflammation

    Study Rationale: One of the hallmarks of Parkinson’s disease (PD) is neuroinflammation. During this dynamic process, the brain’s immune cells, called microglia, become activated and can either prolong...

  • Research Grant, 2023
    Mobility Matters: A Mobilise-D Extension Study

    Study Rationale: Mobility, the ability to physically move around, is vitally important and key to an individual’s independence. Although loss of mobility is a key feature in Parkinson’s disease (PD)...

  • Improved Biomarkers and Clinical Outcome Measures, 2020
    Developing Assays to Quantify Cys106 of DJ-1 in Distinct Oxidized States as a Potential Diagnostic Tool for Parkinson’s Disease

    Study Rationale: 
    Currently, there are no tools to predict whether someone is at risk of developing Parkinson’s disease or to diagnose the early stages of the disease before motor symptoms can be...

  • Target Advancement Program, 2020
    Determining the Ligase and DUB Landscape of Mitochondrial and Alpha-synuclein Turnover

    Study Rationale:        
    Research suggests that accumulation of faulty mitochondria (the “powerhouse” of the cell) or mutated forms of the protein alpha-synuclein in the brain contribute to the...

  • Therapeutic Pipeline Program, 2020
    Identification and Characterization of Small Molecule Activators of ATP13A2 for Parkinson’s Disease Therapy

    Study Rationale:
    In Parkinson’s disease, neurons degenerate because of a disturbed function of the lysosomes and mitochondria. The lysosomal transporter ATP13A2 (PARK9) is genetically implicated in...

  • Target Advancement Program, 2020
    Identification of ASC as a Disease-modifying Therapeutic Target in Parkinson’s Disease

    Study Rationale:
    Inflammasomes are large multiprotein complexes that play a central role in the innate immune system, the body’s first line of defense against microbes. Inflammasomes are key drivers...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.